Martek Stock To Raise $11 Mil. For Plant Upgrades; Firm Files Patent Suit
This article was originally published in The Tan Sheet
Executive Summary
Martek Biosciences' recent stock sale under a shelf registration statement is expected to bring in $11.2 mil. and allow the firm further breathing room to continue expanding its major manufacturing facilities
You may also be interested in...
Martek Reaches Beyond Infant Formula To Grab Perinatal, Food Markets
Martek Biosciences is supplying DHA for Mission Pharmacal's upcoming Rx perinatal dietary supplement Citracal + DHA, the firm announced during a presentation to investors
Martek Reaches Beyond Infant Formula To Grab Perinatal, Food Markets
Martek Biosciences is supplying DHA for Mission Pharmacal's upcoming Rx perinatal dietary supplement Citracal + DHA, the firm announced during a presentation to investors
Martek Reaches Beyond Infant Formula To Grab Perinatal, Food Markets
Martek Biosciences is supplying DHA for Mission Pharmacal's upcoming Rx perinatal dietary supplement Citracal + DHA, the firm announced during a presentation to investors